GlassScriptPhysician profile
Bruce K Branin
NPI 1144435785
$3,590.14
in general payments reported to CMS, 2019-2025
32 companies · $51.07 in 2025
The $51.07 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $774 · 2020: $677 · 2021: $1,207 · 2022: $767 · 2023: $75.25 · 2024: $38.32 · 2025: $51.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $164.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $509.34 | 2019-2024 | Jardiance, Zepbound |
| Novo Nordisk INC | $380.93 | 2019-2022 | |
| Abbvie INC. | $350.24 | 2021-2023 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $347.99 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $332.53 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $260.76 | 2019-2022 | |
| Pfizer INC. | $218.22 | 2019-2021 | |
| Abbott Laboratories | $172.34 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $139.30 | 2019-2022 | |
| Amgen INC. | $120.31 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $98.66 | 2019-2022 | |
| Allergan, INC. | $86.54 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.20 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $73.73 | 2021-2022 | |
| Astellas Pharma US INC | $56.36 | 2020-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $48.98 | 2021-2022 | |
| Clarus Therapeutics INC. | $42.23 | 2021 | |
| Amarin Pharma, INC. | $35.22 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $34.16 | 2022 | |
| Arbor Pharmaceuticals, INC. | $29.20 | 2019-2020 | |
| Boston Scientific Corporation | $29.12 | 2025 | General - Pain Management |
| Shire North American Group INC | $26.68 | 2019 | |
| Nevro Corp. | $20.27 | 2022 | |
| Mylan Specialty L.P. | $20.00 | 2021 | |
| Sanofi-Aventis U.S. LLC | $19.11 | 2019 | |
| Eisai INC. | $16.45 | 2020 | |
| Adlon Therapeutics L.P. | $12.65 | 2021 | |
| Ironshore Pharmaceuticals INC. | $12.36 | 2019 | |
| Grifols USA, LLC | $12.26 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Branin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.